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Abstract
The functional impact of altered drug transport protein expression on the systemic 
pharmacokinetics of morphine, hepatically-derived morphine glucuronide (morphine-3- and 
morphine-6-glucuronide), and fasting bile acids was evaluated in patients with biopsy-confirmed 
non-alcoholic steatohepatitis (NASH) compared to healthy subjects. The maximum concentration 
(Cmax) and area under the concentration-time curve (AUC0-last) of morphine glucuronide in serum 
were increased in NASH patients (343 vs. 225nM and 58.8 vs. 37.2μM*min, respectively; 
P≤0.005); morphine pharmacokinetics did not differ between groups. Linear regression analyses 
detected an association of NASH severity with increased morphine glucuronide Cmax and 
AUC0-last (P<0.001). Fasting serum glycocholate, taurocholate and total bile acid concentrations 
were associated with NASH severity (P<0.006). Increased hepatic basolateral efflux of morphine 
glucuronide and bile acids is consistent with altered hepatic transport protein expression in 
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patients with NASH and may partially explain differences in efficacy and/or toxicity of some 
highly transported anionic drugs/metabolites in this patient population.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease ranging from 
simple steatosis to cirrhosis of the liver. Non-alcoholic steatohepatitis (NASH) is an 
intermediate pathologic state on the pathway from simple steatosis to cirrhosis that is 
characterized by hepatocyte steatosis, ballooning, inflammation and fibrosis.(1) NASH is 
strongly associated with insulin resistance and metabolic syndrome. NAFLD is believed to 
be the most common cause of chronic liver disease in the Western world and is recognized 
as a major public health concern.(2) Equally concerning is the fact that many patients are 
unaware of their disease until progression to advanced stages has occurred.(3) Left 
untreated, NAFLD and NASH can progress to advanced fibrosis, cirrhosis and 
hepatocellular carcinoma, ultimately requiring liver transplantation in some patients.(1) 
Medications such as metformin, pioglitazone, rosiglitazone and rosuvastatin have been used 
to improve insulin resistance to reverse the inflammation associated with NAFLD and 
prevent fibrosis.(4-7) Although modest reductions in serum liver function markers were 
observed, histologically, the progression of fibrosis was not reliably prevented or did not 
regress for any tested pharmacologic intervention. The major site of action of these 
medications is within hepatocytes; thus, diminished activity may be partially due to 
decreased hepatocellular concentrations.(8)
The dynamic interplay between hepatic sinusoidal uptake transporters, drug metabolizing 
enzymes, and basolateral and/or canalicular efflux transporters regulates hepatocellular 
concentrations and exposure to medications and their metabolites.(9, 10) Modest changes in 
one or more of these processes can impact systemic and/or hepatocellular concentrations.
(11, 12) Bile acid concentrations are regulated by these factors, as well as de novo synthesis 
within hepatocytes; intestinal hydrolysis and transporters, which facilitate reabsorption, also 
contribute to bile acid exposure.(13) Recently, expression of many uptake and efflux 
transporters and drug metabolizing enzymes was evaluated in liver samples from patients 
with NASH compared to healthy subjects. In general, NASH down-regulated transport 
proteins responsible for hepatic uptake of drugs and bile acids (e.g., organic anion 
transporting polypeptides [OATPs], sodium-taurocholate cotransporting polypeptide 
[NTCP]) and up-regulated hepatic excretory proteins (e.g., multidrug resistance-associated 
protein [MRP]3, MRP4, breast cancer resistance protein [BCRP], MRP2).(14-17) However, 
the impact of the observed up-regulation in MRP2 protein is difficult to predict due to 
altered localization of this canalicular protein. In contrast to the predictable nature of the 
changes observed with transporters (i.e., decreased uptake and increased efflux), cytochrome 
P450s, uridine-5’-diphospho-glucuronosyltransferases (UGTs), and sulfotransferases 
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generally were unchanged with few exceptions.(16) Altered transporter expression in NASH 
patients is expected to impair hepatic uptake and shift excretion of anionic drugs/
hepatically-derived metabolites from bile to sinusoidal blood, resulting in decreased liver 
exposure and increased systemic concentrations/exposure. These changes may decrease 
activity or efficacy of highly transported bioactive endogenous substrates, medications 
and/or hepatically-derived metabolites with an intrahepatic site of action.(4-7)
Despite a general understanding of the impact of decreased transporter-mediated hepatic 
uptake of medications on systemic and hepatic concentrations(11, 18), the importance of 
altered basolateral efflux is underappreciated. The functional impact of altered uptake and/or 
efflux transporter expression has not been evaluated in NASH patients.(9, 10, 19) Therefore, 
the primary objective of this study was to assess the functional impact of altered hepatic 
transporter expression in patients with biopsy-confirmed NASH compared to healthy 
subjects. Hepatically-derived glucuronide conjugates of morphine were selected as a 
phenotypic probe to evaluate MRP3 function for several reasons: 1) morphine enters the 
hepatocyte via a combination of passive diffusion and active transport by organic cation 
transporter 1 (OCT1)(20) and is unaffected by changes in uptake transporters known to be 
altered in NASH(17); 2) hepatic expression of UGT2B7, which metabolizes morphine to 
morphine-3- and -6-glucuronide, is not altered in NASH(9, 10, 16, 21); 3) morphine is 
eliminated almost exclusively as morphine glucuronide in the urine, suggesting that 
basolateral efflux is important in the systemic and hepatic disposition; and 4) MRP3 appears 
to be the only protein that transports hepatically-derived morphine glucuronide into 
sinusoidal blood.(22, 23) Additionally, Mrp3 protein expression positively correlated with 
basolateral efflux clearance of the Mrp3 substrate acetaminophen glucuronide in rat, and 
human UGT2B7 polymorphisms that exhibit decreased function appear to have minimal 
impact on the systemic concentrations of morphine glucuronide.(24, 25) Therefore, systemic 
morphine glucuronide concentrations should increase in patients with NASH due to MRP3 
up-regulation compared to healthy subjects, whereas the pharmacokinetics of parent 
morphine should be unaffected. Altered transporter expression in patients with NASH could 
have implications for other MRP3-transported substrates such as endogenous glycocholate 
and taurocholate.(26) Although bile acids are formed in the liver and generally undergo 
efficient enterohepatic recirculation(27), increased serum concentrations under fasting 
conditions would be consistent with decreased hepatic uptake and increased basolateral 
efflux. Therefore, the secondary objective of this study was to evaluate fasting serum 
concentrations of total bile acids, glycocholate and taurocholate in patients with NASH 
compared to healthy subjects.
Results
Study Subjects
Twenty-one volunteers (14 healthy subjects and 7 patients with biopsy-confirmed NASH) 
were studied (Table 1; see Supplementary Figure 1 for a summary of volunteer recruitment, 
enrollment and completion). In selecting healthy subjects, effort was made to recruit a 
control cohort comparable to the NASH cohort with respect to age, sex, race, and ethnicity. 
As expected, patients with NASH weighed more and had a higher body mass index (BMI) 
Ferslew et al. Page 3













than the healthy subjects. Serum creatinine was within normal limits for both groups (Table 
2), resulting in estimated glomerular filtration rates within normal limits for all subjects. 
Compared to healthy subjects, patients with NASH had higher serum alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), triglycerides, and insulin resistance as 
demonstrated by increased fasting glucose and insulin levels, as well as homeostasis model 
for assessing insulin resistance (HOMA-IR) scores, and decreased HDL (Table 2). Biopsy 
results indicated that all NASH patients had a NAFLD activity score (NAS) of at least 4, 
with a maximum score of 6 and minimal to moderate (F0 to F3) fibrosis (Table 2).
Morphine Pharmacokinetics
The presence of NASH had minimal impact on the pharmacokinetics of intravenously 
administered morphine (Figure 1A and Table 3). No statistically significant mean 
differences were observed between subject groups for maximum serum concentration 
(Cmax), area under the serum concentration-time curve to the last measured timepoint 
(AUC0-last), AUC extrapolated to infinity (AUC0-∞), total mass of morphine excreted in 
urine over the 8-hr collection interval (Xurine), terminal volume of distribution (Vz), total 
body clearance (CL), or half-life (t1/2). Cmax for each subject was always at the timepoint 
immediately following the end of the infusion. The geometric mean Cmax and AUC0-last for 
NASH patients were within 12% and 17%, respectively, of the corresponding values for 
healthy subjects (Table 3).
Morphine Glucuronide Pharmacokinetics
The geometric mean morphine-3-glucuonide AUC0-∞ was approximately 10-fold higher 
than morphine-6-glucuronide AUC0-∞ in healthy subjects (Figure 1), consistent with 
literature reports.(28, 29) The percent difference in Cmax, time to reach Cmax (Tmax), 
AUC0-last, AUC0-∞, and t1/2 for morphine-3-glucuronide in both subject groups (Figure 1) 
exhibited similar trends as morphine-6-glucuronide when evaluated separately. Therefore, 
for brevity, morphine-3-glucuronide and morphine-6-glucuronide molar concentrations were 
combined for statistical analysis and reported as “morphine glucuronide”.
Morphine glucuronide geometric mean Cmax and AUC0-last were 52% and 58% higher, 
respectively, in patients with NASH compared to healthy subjects following intravenous 
morphine administration (P = 0.001 and P = 0.005, respectively; Figure 1B and Table 3). 
From controls to NASH patients, the median Tmax shifted by 61% from 38 min to 15 min (P 
= 0.427). Although patients with NASH had slightly higher morphine glucuronide Xurine, 
this difference was small (0.85 μmol) and the t-test was inconclusive (P = 0.437; Table 3). 
The difference in morphine glucuronide t1/2 also was small (-41 minutes) and the t-test was 
inconclusive (P = 0.146; Table 3).
Fasting Bile Acids Serum Concentrations
Fasting total bile acids, glycocholate and taurocholate serum concentrations in healthy 
subjects were 1.5±0.6, 0.08±0.06 and 0.02±0.02 μM, respectively, similar to previous 
reports.(30) Total bile acid, glycocholate and taurocholate serum concentrations in patients 
with NASH were 2.5-, 3.1-, and 5.7-fold higher, respectively, compared to healthy subjects 
(P = 0.022, P = 0.017, P = 0.047, respectively; Figure 2).
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Linear regression models detected an association between the NASH severity score (NAS
+Fibrosis scores) and fasting total bile acid, glycocholate and taurocholate serum 
concentrations (Figure 3). Linear regression models also were used to identify clinical 
predictors of morphine glucuronide disposition. Considered individually, the clinical 
predictors identified included NASH severity score, waist circumference, waist-to-hip 
circumference ratio, ALP, fasting glucose, triglycerides, HDL, insulin and HOMA-IR (Table 
4). When these candidate clinical predictors of morphine glucuronide were included together 
in multivariable regression models for Cmax and AUC0-last, only NASH severity remained 
statistically significantly (Figure 3 and Table 4).
Discussion
To the authors’ knowledge, this study is the first to assess the impact of a disease-associated 
increase in hepatic basolateral efflux transporter expression on drug disposition in humans. 
This study demonstrated that patients with NASH, a liver disease associated with increased 
protein expression of the hepatic basolateral efflux transporter MRP3, exhibited increased 
systemic concentrations of morphine glucuronide.(15) The primary endpoint, Cmax of 
hepatically-derived morphine glucuronide, which was selected based on the mathematical 
model developed a priori, was higher in patients with NASH compared to healthy subjects 
(Figure 1; Table 3). Increased morphine glucuronide Cmax in NASH likely reflects increased 
hepatic basolateral efflux clearance mediated by MRP3, which transports glucuronide 
conjugates from hepatocytes to blood.(15, 22) Multivariable regression analysis of clinical 
liver function markers, insulin resistance metrics and biopsy results indicated that only 
biopsy-determined NASH severity (NAS+Fibrosis) independently predicted increased 
morphine glucuronide Cmax and AUC0-last (Figure 3; Table 4). The secondary endpoint, 
fasting bile acid serum concentrations, was statistically significantly higher in patients with 
NASH compared to healthy volunteers and positively correlated with NASH severity based 
on biopsy scores (Figure 2). Specifically, serum concentrations of glycocholate and 
taurocholate, bile acids that are MRP3 substrates(26), were increased in NASH patients with 
varying degrees of disease progression/inflammation. These findings suggest that in the 
progressive inflammatory states investigated in this study, increasing NASH severity may 
further increase MRP3-mediated efflux clearance.
Recently, altered drug metabolizing enzyme and transporter expression was evaluated in 
liver biopsies from healthy subjects and from patients exhibiting varying degrees of 
NAFLD, from simple steatosis to steatohepatitis.(14-17) Through what appears to be an 
adaptive mechanism to prevent further hepatic damage, uptake transporters are generally 
down-regulated, whereas efflux transporters are up-regulated. Although these changes in 
expression patterns may protect the hepatocyte from toxins (e.g., increased bile acid 
concentrations), such alterations may have unanticipated effects on the efficacy of 
medications that rely on these transporters for hepatic entry and retention. Results from this 
study and prior pharmacokinetic modeling of morphine/morphine glucuronide hepatic 
exposure are consistent with this notion.(31)
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Although systematic, comprehensive investigations of altered drug metabolism and/or 
transport have not been conducted for most hepatic disease states, clearance of choline 
following oral administration to patients with NASH was decreased compared to healthy 
volunteers.(32) The authors proposed that the increased systemic choline concentrations 
were due to decreased metabolism secondary to reduced microsomal triglyceride transfer 
protein function in patients with NASH. Alternatively, reduced hepatic uptake and/or 
increased basolateral efflux could contribute to increased systemic choline concentrations. 
(33) Altered hepatic drug transport was observed in rodent models of NASH.(34) For 
example, increased systemic and decreased hepatic exposure to simvastatin acid were 
reported in rats with diet-induced NASH compared to control.(34) Additionally, bile acid 
concentrations were increased in rodent models of steatosis.(35) Clearly, a growing body of 
literature demonstrates the importance of altered hepatic uptake and efflux on the systemic 
and hepatic disposition of many drugs, metabolites, and endogenous substrates.(32, 34, 35)
Altered hepatic transport due to disease or drug-drug interactions that shifts the predominant 
excretion pathway of drugs/metabolites can have unexpected consequences on systemic and 
hepatic disposition and ultimately, therapeutic efficacy and/or toxicity. For example, 
coadministration of cyclosporine, a potent inhibitor of hepatic transport proteins, with 
mycophenolate mofetil in transplant patients unexpectedly decreased mycophenolic acid 
systemic exposure.(36) Further investigation revealed that inhibition of canalicular transport 
likely shifted the excretion profile of mycophenolic acid glucuronide from predominantly 
biliary, with subsequent enterohepatic recycling of mycophenolic acid, to hepatic basolateral 
efflux and ultimately urinary excretion.(37) The recent failure of rosuvastatin to decrease 
histologic severity or prevent worsening fibrosis in patients with NASH(7) may be an 
example of altered transporter-mediated pharmacokinetics; decreased hepatic uptake(17, 
34), with a shift toward basolateral excretion and ultimately terminal urinary elimination(38, 
39), potentially decreased the hepatic exposure and therapeutic efficacy of rosuvastatin. 
These examples emphasize the dynamic interplay between MRP3 and MRP2 and the need to 
better understand how altered hepatic transport impacts the systemic and hepatic disposition 
of both endogenous and exogenous compounds.
Altered hepatic transporter expression may influence the disposition of endogenous 
compounds (e.g., bile acids) in addition to drugs/metabolites. Bile acids are formed in the 
liver and undergo efficient enterohepatic recirculation, resulting in low systemic serum 
concentrations.(30) Fasting serum concentrations of total bile acids, glycocholate, and 
taurocholate were increased 2.5- to 5.7-fold in patients with NASH compared to healthy 
controls. These changes correlate with previous reports of intrahepatic bile acid 
concentrations in liver tissue from patients with NASH compared to healthy subjects.(40) In 
addition to MRP3 up-regulation, and down-regulation of NTCP and OATPs, taurine 
conjugation is increased.(40) Studies are ongoing to investigate the influence of altered bile 
acid profiles in NASH patients on drug disposition, efficacy and toxicity.
Some limitations are associated with this work. First, this study enrolled a relatively small 
number of patients with NASH. However, low enrollment was balanced by increased 
precision obtained by recruiting 2:1 healthy subjects to NASH patients. Second, to define a 
homogenous population of healthy subjects, only subjects without insulin resistance and 
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with normal liver enzymes were enrolled in an effort to exclude subjects with prevalent 
steatosis. Patients with probable steatosis were excluded for two reasons: 1) since biopsies 
were not obtained as part of this study and the prevalence of undiagnosed NAFLD/NASH is 
high in the overall population, differentiation of non-NAFLD healthy subjects with insulin 
resistance vs. prevalent simple steatosis or NASH was not possible, and 2) changes in 
transporter-mediated drug/metabolite disposition are only expected following onset of 
inflammation (i.e., NAS>3) when efflux transporter expression is up-regulated.(15, 17) 
Although clinical liver biopsy results were used to identify patients with NASH, 
quantification of transport protein expression in these biopsies was not possible, and ethical 
considerations precluded an additional biopsy. Hepatic MRP3 and MRP2 protein expression 
were shown previously to be increased in patients with NASH; however, MRP2 protein 
appeared to be internalized.(15) Although MRP2 function in NASH patients is unknown, 
mathematical modeling suggested that a ±2-fold change in MRP2-mediated clearance 
should not meaningfully impact morphine glucuronide Cmax or confound our interpretation 
of the data that changes in systemic concentrations were due to increased MRP3-mediated 
efflux clearance. Nevertheless, the possibility that altered MRP2 function influenced 
morphine glucuronide systemic concentrations cannot be dismissed.(31)
In conclusion, patients with NASH exhibited increased morphine glucuronide Cmax and 
AUC0-last, as well as fasting serum concentrations of total bile acids, glycocholate, and 
taurocholate compared to healthy volunteers. These changes are consistent with NASH-
associated alterations in expression of hepatic transport proteins reported previously (e.g., 
increased MRP3). Increased Cmax and exposure to morphine glucuronide conjugates, as well 
as bile acids, positively correlated with biopsy-determined NASH severity. Given the 
increasing incidence of NASH, changes in hepatic transport proteins contributing to altered 
disposition of drugs/metabolites and bile acids may have a major impact on drug efficacy 
and/or toxicity. Understanding the consequences of alterations in transporter-mediated 
disposition is paramount for new medications that will be administered to patients who may 
have underlying, undiagnosed liver disease.
Patients and Methods
Patients
Healthy subjects and patients with biopsy-confirmed NASH, between 18 and 65 years of age 
and of any race and ethnicity who reported drinking less than 20 g/day of alcohol, were 
enrolled in the study. General inclusion criteria for both groups were normal serum 
creatinine and total bilirubin levels; nonreactive HIV, hepatitis B antigen and hepatitis C 
antibody; no history of gastrointestinal surgery, autoimmune disease or other GI/liver 
disease. Subjects were excluded if they were unable to pass a urine drug screen for opiates, 
marijuana and barbiturates; female subjects were excluded if they were, or were trying to 
become, pregnant. Healthy volunteers were eligible if all of the following applied: ALP and 
ALT levels within normal limits; HOMA-IR score < 2.5; BMI ≤ 30 kg/m2; not taking any 
concomitant medications other than birth control or a standard multivitamin. In selecting 
healthy subjects, effort was made to recruit a control cohort comparable to the NASH cohort 
with respect to age, sex, race, and ethnicity. Patients with NASH were recruited from the 
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University of North Carolina at Chapel Hill (UNC-CH) hepatology clinic and were eligible 
for enrollment if all of the following applied: biopsy confirmed non-cirrhotic NASH with 
non-alcoholic fatty liver disease activity score (NAS) >3 (41); BMI ≤ 45 kg/m2; no 
treatment for type 2 diabetes other than metformin; no milk thistle products or high dose 
antioxidant treatment during the prior 30 days; absence of prior treatment with NASH-
inducing drugs (i.e., tamoxifen, amiodarone, valproate, methotrexate). Written informed 
consent was obtained from all subjects. This study was approved by the UNC Biomedical 
Institutional Review Board and published in ClinicalTrials.gov (NCT01766960).
Study Design
This single center, comparative cohort, proof-of-concept study evaluated morphine and 
morphine glucuronide pharmacokinetics in healthy subjects and patients with NASH. 
Subjects and patients who met all inclusion/exclusion criteria fasted overnight prior to 
presenting to the Clinical and Translational Research Center at UNC-CH Hospitals. 
Following admission, hip and waist circumferences were measured, vital signs were 
assessed, and an i.v. catheter was placed in each arm delivering 50 mL/hr of either normal 
saline or lactated Ringer's solution. Patients ate a standardized breakfast sandwich 
containing 23.9 g of fat and finished within 30 min. Two hours after completion of the meal, 
a 5 mg i.v. dose of morphine sulfate was infused over 5 min. Blood (5 mL) was collected in 
glass tubes pre-dose, end of infusion (0), and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 
360, 420, and 480 min after the end of the infusion; urine was collected at 4-hr intervals 
after the end of the infusion. Blood samples were allowed to clot for 30 to 60 min, and 
serum was separated, divided into aliquots and frozen. Serum and urine samples were stored 
at -80°C until analysis. Following discontinuation of both i.v. lines, patients were 
administered a safety questionnaire and discharged to a waiting third party to be driven 
home.
Sample Processing and Analysis
Morphine serum and urine samples were analyzed in batches every three months according 
to a validated bioanalytical method (see supplementary materials).(42) Briefly, aliquots (100 
μL) of serum and urine samples were transferred to a 96-well plate insert; proteins were 
precipitated with 600 μL acetonitrile containing morphine-d3, morphine-3-glucuronide-d3 
and morphine-6-glucuronide-d3 (100 ng/mL) as internal standards (Lipomed, Cambridge, 
MA). Samples were mixed by vortex for 2.5 min and centrifuged (3,000g for 20 min at 4° 
C). Supernatant (500 μL) was transferred to a separate 96-well plate insert, dried under 
nitrogen, and 100 μL of 50:50 water:methanol were added to each insert. Calibration 
solutions and quality controls containing all three analytes (Lipomed) were prepared 
similarly using pooled blank plasma or urine.
Morphine and morphine glucuronide concentrations were measured by high resolution 
liquid chromatography coupled with an ABSciex 5600 TripleTOF mass spectrometer (LC-
MS/MS) as described previously.(42) For morphine analysis, the product of 286.14 with an 
exact m/z of 286.1200 was monitored. Deuterated morphine, morphine-3- and -6-
glucuronide, and deuterated internal standards for the glucuronides were monitored using 
exact m/z's of 289.1600, 462.1700, and 465.1900, respectively. The two morphine 
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glucuronides were separated chromatographically; insource fragmentation from morphine 
glucuronide to morphine was negligible.
All 30 bile acid standards were obtained from Steraloids Inc. (Newport, RI), and stable 
isotope-labeled standards were obtained from C/D/N Isotopes Inc. (Quebec, Canada). 
Sample preparation followed a published method with modifications.(30) Briefly, 150 μL of 
internal standard was added to 50 μL of serum or standard solution. After centrifugation, the 
supernatant was transferred to a clean plate and evaporated to dryness. The residue was 
reconstituted with 20 μL of acetonitrile and 20 μL of water and filtered through a 0.45 μm 
membrane before injecting 5 μL into the UPLC-MS/MS (ACQUITY UPLC-Xevo TQ-S, 
Waters Corp., Milford, MA) to quantify 30 bile acids in serum. The optimized instrument 
settings are described in the supplementary materials. The sum of all measured bile acids is 
reported as total bile acids.
Mathematical Modeling and Simulation for Sample Size Calculation
A previously published whole body physiologically-based pharmacokinetic (PBPK) model 
was used as a base model to describe the disposition of morphine and morphine glucuronide.
(43) The model was developed using Phoenix® WinNonlin® (v6.3; Certara, St. Louis, MO) 
and was parameterized with adult reference values.(43, 44) The kinetics of morphine in all 
tissues was assumed to be described by a flow-limited, well-mixed model; morphine 
glucuronide distribution was governed by hepatic MRP3-mediated basolateral, and MRP2-
mediated canalicular, efflux clearances (CLMRP3 and CLMRP2, respectively). Serum 
morphine-3- and -6-glucuronide were modeled as a single metabolite (morphine 
glucuronide). Morphine glucuronide was assumed to be eliminated by the kidney via 
glomerular filtration. Model optimization was guided by assessing the model output 
compared to data extracted from published clinical studies.(28, 29, 45-48) The model was 
used to simulate altered disposition of morphine and metabolites in virtual patients. Patients 
with NASH were assumed to have a 3-fold higher morphine glucuronide CLMRP3 based on 
published MRP3 protein expression compared to healthy subjects.(15) Simulations 
demonstrated a 36% increase in glucuronide Cmax (data not shown).(31) The difference in 
mean Cmax was selected as the primary endpoint. Based on the modeling output and 
estimates of variability from two studies using similar analytical techniques(28, 47), the 
number of subjects recruited (14 healthy subjects, 7 NASH patients) was projected to 
provide sufficient power to reject the null hypothesis of no difference in Cmax between 
subject groups.
Pharmacokinetic Data Analysis
Morphine, morphine-3-glucuronide and morphine-6-glucuronide pharmacokinetics were 
evaluated using non-compartmental analysis (Phoenix® WinNonlin® v6.3). Cmax, time to 
reach Cmax (Tmax), last measureable concentration (Clast), terminal volume of distribution 
(Vz, for morphine only) and terminal elimination rate constant (λz) were estimated from the 
serum concentration-time profile. The area under the concentration-time curve (AUC) from 
time zero to the last measurable concentration (AUC0-last) was determined using a linear-up 
log-trapezoidal-down algorithm. Total AUC (AUC0-∞) was calculated as the sum of 
AUC0-last and Clast/λz. The terminal half-life (t1/2) was calculated as 0.693/λz. Total body 
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clearance (CL) of morphine was calculated as the ratio of dose to AUC0-∞. The total mass 
of morphine and morphine glucuronide excreted in urine over the 8-hr collection interval 
(Xurine) was calculated as the product of urine concentration and volume of urine collected. 
Concentrations below the limit of quantification were excluded from analysis.
Statistical Analysis Strategy
Morphine and morphine glucuronide pharmacokinetics are presented as geometric means 
and 95% CIs with the exception of Tmax, which is presented as median and range. Log 
transformed metrics were compared between groups using a two-tailed t-test of size α = 
0.05; the Wilcoxon Mann-Whitney test was used to detect cohort differences in median 
Tmax.
Linear regression models were used to identify clinical predictors of morphine glucuronide 
AUC0-last and Cmax. Candidate clinical predictors included age, BMI, body weight, waist 
and hip circumference, waist-to-hip ratio, SCr, ALT, ALP, albumin, total bilirubin, NASH 
severity score, fasting glucose, triglycerides, HDL and LDL cholesterol, insulin, and 
HOMA-IR. Separate models for AUC0-last and Cmax were fit for each of these predictors. 
Clinical variables with statistically significant predictive value were included in a 
multivariable regression model subject to backward elimination. The criterion for retention 
in the multivariable model was P ≤ 0.10. NASH severity scores for healthy subjects were 
assumed to be zero. All statistical computations for the primary analyses were performed 
using SAS software (v9.3; SAS Institute, Inc., Cary, NC). Unless otherwise stated, 
tabulations are presented as mean and standard deviation. Cohort comparisons relied on a 
two-tailed pooled-variance t-test procedure of size α=0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cmax maximum serum concentration
MRP multidrug resistance-associated protein
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NAFLD non-alcoholic fatty liver disease
NAS NAFLD activity score
NASH non-alcoholic steatohepatitis
OATPs organic anion transporting polypeptides
PBPK physiologically-based pharmacokinetic
NTCP sodium-taurocholate cotransporting polypeptide
UGTs uridine 5’-diphospho-glucuronosyltransferases
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What is the current knowledge on the topic?
Hepatic transport protein expression is altered in patients with NASH (e.g., MRP3 up-
regulation), a prevalent form of liver disease associated with increased mortality. 
However, functional changes in transporter-mediated drug disposition have not been 
evaluated in NASH.
What question did the study address?
Hepatically-derived morphine glucuronide and fasting bile acid serum concentrations 
were evaluated as a phenotypic probe of MRP3 in biopsy-confirmed NASH patients vs. 
healthy subjects.
What this study adds to our knowledge?
Morphine glucuronide systemic exposure and bile acid serum concentrations were 
significantly higher in NASH patients vs. healthy subjects. NASH severity was 
significantly associated with morphine glucuronide and bile acid serum concentrations.
How this might change clinical pharmacology and therapeutics?
NASH patients may exhibit increased systemic exposure to MRP3 substrates (e.g., 
anionic drugs/metabolites, bile acids). These changes may lead to increased systemic 
toxicities and decreased hepatic drug efficacy. Understanding the consequences of altered 
transporter-mediated disposition, including the dynamic interplay between MRP3 and 
MRP2, is paramount for medications used in NASH. This knowledge may help guide 
drug/dose selection in NASH.
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Morphine (circles, A), morphine-3-glucuronide (triangles, B), and morphine-6-glucuronide 
(squares, B) serum concentration vs. time profiles in healthy subjects (grey) and patients 
with NASH (black). Data are presented as geometric mean and 95% confidence intervals.
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Fasting total bile acids, glycocholate and taurocholate serum concentrations in healthy 
subjects (grey bars) and patients with NASH (black bars). Data are presented as mean ± SE; 
* P<0.05. Results of univariate linear regression analysis of NASH severity (NAS+Fibrosis; 
sum of non-alcoholic fatty liver disease activity and fibrosis scores) with bile acid serum 
concentrations are included. Data are presented as the regression parameter estimate (β) with 
SE of the parameter estimate in parentheses.
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Association of the NASH severity score (NAS+Fibrosis severity scores) with morphine 
glucuronide Cmax (A) and AUC0-last (B). Values for patients with NASH (triangles) and for 
healthy subjects (circles) are shown with the linear regression and its 95% confidence limits 
(shaded area). The NASH severity score is the sum of the NAS and fibrosis biopsy scores; 
for healthy subjects, an imputed value of zero was assumed.
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Table 1
Demographic characteristics of study participants.









Age (years) 42 (13) 48 (10)




Body mass index (kg/m2) 26 (2.7) 32 
*
 (5.2)
















Women 0.84 (0.06) 1.08 (0.36)
Data presented as mean (SD)
*
P<0.05, Student's two-tailed t-test comparing healthy subjects to patients with NASH
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Table 2
Serum chemistries, insulin resistance and liver biopsy grade.
Clinical Parameter Healthy NASH
Creatinine (mg/dL) 0.82 (0.14) 0.80 (0.22)








Albumin (g/dL) 4.3 (0.3) 4.5 (0.4)
Total Bilirubin (mg/dL) 0.64 (0.22) 0.81 (0.29)
Cholesterol (mg/dL) 189 (40) 190 (48)








LDL, calculated (mg/dL) 102 (34) 101 (47)












Total NAS Score N/A 5 (4-6)
    Steatosis N/A 2 (1-3)
    Hepatocyte Ballooning N/A 2 (1-3)
    Inflammation N/A 1 (0-2)
Fibrosis N/A 1 (0-3)
NAS + Fibrosis N/A 7 (4-8)
Data presented as mean (SD); biopsy scoring presented as median (range)
ALT; alanine aminotransferase
ALP; alkaline phosphatase
HDL; high-density lipoprotein cholesterol
LDL; low-density lipoprotein cholesterol
NAS: non-alcoholic fatty liver disease activity score
HOMA-IR; homeostasis model for assessing insulin resistance
N/A; not applicable
*
P<0.05, Student's two-tailed t-test comparing healthy subjects to patients with NASH
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Table 3
Pharmacokinetic parameters for morphine and morphine glucuronide determined by non-compartmental 
analysis in healthy subjects and patients with NASH.
Morphine Morphine Glucuronide
a
Metric Healthy NASH Healthy NASH






0 (0-0) 0 (0-0) 38 (5-240) 15 (5-90)
AUC0-last (μM*min) 4.1 (3.1-5.3) 3.5 (2.4-5.0) 37.2 (31.6-43.7) 58.8 
*
 (41.6-83.0)
AUC0-∞ (μM*min) 5.5 (4.3-6.9) 5.2 (3.7-7.4) 45.2 (37.5-54.5) 67.8 
*
 (46.7-98.5)
Vz (L) 153 (125-188) 173 (113-264) N/D N/D
CL (L/min) 1.2 (1.0-1.5) 1.3 (0.9-1.8) N/D N/D




0.89 (0.73-1.1) 0.64 (0.52-0.78) 5.4 (4.3-6.8) 6.2 (4.3-9.1)
Data presented as geometric mean (95% CI)
N/D: not determined
a




Total mass excreted over 8-hr collection interval
*
P<0.05, Student's two-tailed t-test of log transformed data comparing healthy subjects to patients with NASH
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Table 4




Parameter β P-value β P-value
NASH Severity 18.51 (4.72) 0.001 4.11 (1.02) 0.001
Waist Circumference 1.96 (0.87) 0.036 0.40 (0.19) 0.051
Waist-to-Hip Ratio 157 (110) 0.170 48.86 (22.62) 0.044
ALP 3.14 (1.07) 0.008 0.59 (0.25) 0.027
Fasting Glucose 2.27 (0.75) 0.007 0.45 (0.17) 0.017
Triglycerides 0.42 (0.17) 0.019 0.09 (0.04) 0.024
HDL −1.75 (0.62) 0.011 −0.20 (0.16) 0.216
Insulin 2.05 (0.78) 0.017 0.38 (0.18) 0.049
HOMA-IR 6.20 (2.35) 0.016 1.15 (0.54) 0.046
Data are presented as the regression parameter estimate (β) (standard error [SE] of the parameter estimate).
b Only NASH Severity remained statistically significant when all significant predictors were included in a multivariable regression model subject 
to backward elimination
ALP; alkaline phosphatase
NAS+Fibrosis; sum of non-alcoholic fatty liver disease activity and fibrosis scores
HOMA-IR; homeostasis model for assessing insulin resistance
a
Sum of molar concentrations of morphine-3- and morphine-6-glucuronide
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